Georgetown University Medical Center

Deglycosylated Anti-amyloid Beta Antibodies

Section: For Industry

Category(ies): CNS Disorders

Reference #: MAYA426503

OTC Contact: Ruchika Nijhara, Ph.D. (Directory Information | Send a Message)

Description

Accumulation of Beta-amyloid (Abeta) in the brain is the pathologic hallmark of Alzheimer’s disease (AD). The present invention relates to deglycosylated monoclonal antibodies that bind beta-amyloid (Abeta). The invention provides such antibodies and pharmaceutical compositions including such antibodies; and also provides nucleic acids encoding the antibodies and the host cells transformed therewith. The technology presents a huge commercial potential in prophylactic, therapeutic, and diagnostic applications.

Applications

Applications:

  • Can be used for immunoprophylaxis and immunotherapy of Alzheimer’s disease.
  • Research tool- for example, these antibodies can be used in immunoassays.
  • Can be used as a diagnostic tool for detecting Abeta in vivo (biological fluids and tissues).
  • Can be used to monitor the course of Alzheimer’s disease.

Advantages:

  • Deglycosylated Abeta antibody as an AD therapeutic can reduce neuroinflammation- a potential cause for meningoencephalitis.
  • Elevate plasma Abeta as glycoslyated antibodies but do not increase cytokine levels
  • Have comparable kinetics to intact glycosylated antibodies.

Advantages

Stage of Development

Stage of Development: Studies done with deglycosylated Abeta antibodies show that they:  (1) maintain Abeta binding affinity. (2) Do not enhance Abeta phagocytosis or cytokine release in primary cultured microglia. (3) Elevate plasma Abeta levels and induce Abeta sequestration to a similar or greater degree compared with intact antibodies in an Alzheimer's transgenic mouse model without or with Abeta plaque pathology. 

Inventor: Matsuoka Yusuji

 

Relevant Publications

“Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration”; Matsuoka et al, Eur J Neurosci. 2007 Nov;26(9):2458-68.

Patent Status

PCT application # PCT/US06/040101, entitled “Deglycosylated Anti-Amyloid Beta antibodies” filed on October 10, 2006.